The CBAVD-CFTR connection is the most clinically important genetic implication of an abnormal semen analysis that GPs must recognise — congenital bilateral absence of the vas deferens (CBAVD) presents in adults as obstructive azoospermia (normal testicular function and FSH, absent vas deferens on clinical examination, normal volume but absent sperm due to blockage). It is directly caused by mutations in the CFTR gene (the cystic fibrosis gene) — approximately 80% of men with CBAVD carry at least one CFTR mutation, and approximately 10-15% carry two mutations. The clinical consequence: if a man with CBAVD (and therefore likely CFTR mutation) uses surgical sperm retrieval (PESA) for IVF with a partner who is also a CFTR carrier, there is a 25% risk of having a child with cystic fibrosis. CFTR testing of BOTH partners is mandatory before any fertility treatment in CBAVD — this is a genetic counselling requirement. GPs who find absent vas deferens on examination in a young man presenting with infertility must refer to andrology AND flag CFTR testing.

The repeat semen analysis before clinical decision-making is a fundamental principle that is often bypassed in primary care — semen quality is highly variable between samples from the same individual, with intra-individual variation in sperm concentration of approximately ±50%. A single abnormal result may not represent the man's average semen quality — it could reflect: a recent febrile illness (fever >38.5°C causes temporary spermatogenic suppression for approximately 3 months — the time for a complete spermatogenic cycle), an inappropriately short or long abstinence period, a technical laboratory error, or incomplete sample collection. The WHO and NICE NG156 (Fertility) both state: a second semen analysis should be performed 2-12 weeks after the first if the initial result is abnormal, before proceeding to further investigations or treatment. GPs who receive a single abnormal result should request a repeat, provide patient education on correct sample collection technique, and advise avoiding febrile illness-related spermatogenic suppression.

The Y chromosome microdeletion testing in severe male infertility is a clinically consequential genetic investigation — Y chromosome microdeletions in the AZFa, AZFb, or AZFc regions account for approximately 10-15% of non-obstructive azoospermia and approximately 5% of severe oligospermia. The clinical significance: AZFa deletions (complete) = Sertoli cell only syndrome — no sperm on testicular biopsy, TESE/mTESE will fail; AZFb deletions (complete) = maturation arrest — sperm retrieval very unlikely; AZFc deletions = most common (approximately 65-70% of AZF deletions) — variable spermatogenesis, sperm retrieval possible in approximately 50-70%. The most important implication: AZF deletions are transmitted on the Y chromosome to any male offspring born via ICSI (intracytoplasmic sperm injection) — the son will inevitably carry the same deletion and will be similarly infertile. Genetic counselling before ICSI is mandatory for all couples where the male partner has a Y chromosome microdeletion.

The varicocoele and male infertility relationship is an area of ongoing clinical debate — varicocoele is the most common identifiable cause of male infertility (found in approximately 15% of men in the general population, but in approximately 35-40% of men presenting for primary infertility evaluation). The physiological basis: a left varicocoele impairs testicular thermoregulation (the pampiniform plexus normally cools arterial blood flowing to the testis — venous reflux from the varicocoele warms the testis, impairing spermatogenesis, which requires temperature 2°C below core body temperature) and allows reflux of adrenal venous blood carrying cortisol and other metabolites that impair spermatogenesis. The treatment evidence: varicocelectomy (surgical ligation or embolisation) improves semen parameters in approximately 60-70% of men with clinical grade 2-3 varicocoele and abnormal semen analysis. NICE NG156 states: 'do not routinely offer varicocele treatment to men whose partners are fertile' (i.e., treatment is for couples with combined infertility where varicocoele repair may improve natural conception or IVF outcomes).

The GP couple-centred approach to infertility investigation is the most efficient clinical pathway — male and female partner investigations should be initiated simultaneously, not sequentially (waiting for male results before investigating the female partner or vice versa wastes months). NICE NG156 recommends that both partners are investigated at the same time. The GP primary investigation set: for the male partner — two semen analyses + FSH/LH/testosterone + USS testes; for the female partner — day 2-5 FSH/LH/oestradiol + day 21 progesterone + TFTs + pelvic USS + chlamydia/gonorrhoea screen. Both partners investigated and results collated before reproductive medicine referral optimises the specialist consultation, as the couple can be directed immediately toward the appropriate pathway (IUI, IVF, ICSI, donor sperm, donor oocyte) rather than requiring multiple consultations for further GP investigations.

The micro-TESE (microsurgical testicular sperm extraction) for Klinefelter syndrome represents one of the most significant advances in male infertility treatment — Klinefelter syndrome (47,XXY) was historically considered untreatable from a fertility perspective. However, approximately 30-50% of men with Klinefelter syndrome have focal areas of spermatogenesis within the testis (areas where X-inactivation allows normal spermatogenic cell function). Micro-TESE uses an operating microscope to identify and selectively biopsy these dilated, vascularised tubules containing active spermatogenesis, while avoiding the fibrotic pale tubules containing only Sertoli cells. The retrieved sperm are then used for ICSI. Predictors of sperm retrieval success in Klinefelter mTESE: younger age (spermatogenesis deteriorates with age — early referral is critical), testosterone above the lower limit of normal, lower FSH levels. GPs who diagnose or suspect Klinefelter syndrome in a young man wishing future paternity should refer urgently to andrology — even if the patient is not currently planning a family, early sperm banking (if any sperm are present) may preserve future options.

The NHS IVF funding inequity across England is a significant patient and GP advocacy issue — NICE NG156 recommends up to 3 full IVF cycles for eligible women under 40, but NHS England data shows that only approximately 20% of NHS ICS areas offer the full NICE-recommended 3 cycles; approximately 55% offer 1-2 cycles; and some areas offer no NHS-funded IVF at all. This creates a postcode lottery of fertility care that is explicitly at odds with the principle of equitable NHS access. GPs should: (1) be aware of their local ICS fertility commissioning criteria (available from the ICS website or the local fertility unit); (2) advise couples accurately about what is funded locally vs what requires self-funding; (3) advocate for patients who appear to meet NICE criteria but are denied on local criteria grounds; (4) signpost to Patient Advisory Liaison Service (PALS) for patients who wish to challenge commissioning decisions. The HFEA (Human Fertilisation and Embryology Authority) website (hfea.gov.uk) provides reliable information on local fertility treatment options and success rates by clinic.

The anabolic steroid-induced azoospermia is an increasingly prevalent cause of male infertility that is frequently not volunteered by patients without direct questioning — anabolic androgenic steroids (testosterone enanthate, nandrolone, stanozolol, oxandrolone, boldenone) are used by an estimated 3-5% of men in the UK, predominantly by gym-going men aged 18-35. Exogenous androgens profoundly suppress the hypothalamic-pituitary-gonadal axis by negative feedback, reducing FSH to near-zero and halting spermatogenesis completely within 3-4 months of use. The semen analysis typically shows: azoospermia or near-azoospermia with normal testicular volume (the testes are not atrophied — they contain normal seminiferous tubules with adequate Sertoli cell function, but no active spermatogenesis due to absent FSH stimulation). Recovery after cessation: most men recover spermatogenesis within 6-18 months, but approximately 10-15% have prolonged recovery or permanent azoospermia, particularly long-term heavy users. GPs asking about anabolic steroid use should do so in a non-judgmental way: 'Do you use any supplements, performance-enhancing drugs, or anabolic steroids for training purposes?'

The concurrent investigation of both partners from the outset is one of the most evidence-based yet poorly implemented aspects of NICE NG156 — audit data consistently shows that in UK primary care, the male partner is investigated, on average, 3-6 months later than the female partner. This sequential approach wastes months of the couple's reproductive window, particularly significant for female partners over 35 (where ovarian reserve declines rapidly and time-to-pregnancy is a critical variable). The GP implementation: at the first infertility consultation, initiate investigations for BOTH partners simultaneously: SA referral for the male partner + day 2-5 FSH/LH and day 21 progesterone request for the female partner + USS pelvis + chlamydia screen for both. This approach compresses the total investigation time from 9-12 months (sequential) to 3-4 months (simultaneous), significantly improving the timeliness of specialist referral.